EP0951564A1 - Procede pour la detection de composes modulant les effets de la proteine de l'obesite (ob) - Google Patents

Procede pour la detection de composes modulant les effets de la proteine de l'obesite (ob)

Info

Publication number
EP0951564A1
EP0951564A1 EP97910545A EP97910545A EP0951564A1 EP 0951564 A1 EP0951564 A1 EP 0951564A1 EP 97910545 A EP97910545 A EP 97910545A EP 97910545 A EP97910545 A EP 97910545A EP 0951564 A1 EP0951564 A1 EP 0951564A1
Authority
EP
European Patent Office
Prior art keywords
cell line
protein
derived cell
response element
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97910545A
Other languages
German (de)
English (en)
Inventor
Lee James SmithKline Beecham Pharma. BEELEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622867.1A external-priority patent/GB9622867D0/en
Priority claimed from GBGB9622868.9A external-priority patent/GB9622868D0/en
Priority claimed from GBGB9622866.3A external-priority patent/GB9622866D0/en
Priority claimed from GBGB9622850.7A external-priority patent/GB9622850D0/en
Priority claimed from GBGB9622849.9A external-priority patent/GB9622849D0/en
Priority claimed from GBGB9622869.7A external-priority patent/GB9622869D0/en
Priority claimed from GBGB9622848.1A external-priority patent/GB9622848D0/en
Priority claimed from GBGB9622851.5A external-priority patent/GB9622851D0/en
Priority claimed from GBGB9622847.3A external-priority patent/GB9622847D0/en
Priority claimed from GBGB9622865.5A external-priority patent/GB9622865D0/en
Priority claimed from GBGB9622870.5A external-priority patent/GB9622870D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0951564A1 publication Critical patent/EP0951564A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Definitions

  • the invention relates to a novel method and more particularly to a method for the detection of compounds that mimic, potentiate or inhibit the physiological 5 effects of the ob-protein
  • the ob-protein (or leptin) is a secreted hormone that acts as signal from adipose tissue to other organs to regulate weight and energy balance (Zhang et. al, Nature, 1994, 372, 425). Additional roles for the ob-protein in haematopoietic and reproductive function have been suggested (Cioffi et. al. Nature Medicine.
  • Protein molecules that contain a core composed of four ⁇ - helices forming a bundle of up-up-down-down topology comprise a family of cytokines and growth factors. Proteins of this family cause homo- and hetero- oligomerisation of membrane receptors known to activate kinase cascades resulting in gene transcription. Receptors of the family which are activated by
  • oligomerisation fall into two broad classes; those such as epidermal growth factor receptor, which possess integral tyrosine kinase activity in their intracellular domains (A. Ullrich & J. Schlessinger, Cell, 1990, 61, 203-212), and those such as the IL4 and erythropoietin receptors, which lack this activity and mediate their response by way of an associated protein tyrosine kinase (J.N. Ihle et al., TIBS,
  • Both receptor subtypes are activated by cytokines, but the 4- helix bundle proteins activate only the non-integral tyrosine kinase subtype.
  • the non-integral protein tyrosine kinase receptors generally act through a pathway involving Janus kinase (JAK) and their associated signal transducers and activators of transcription (STAT) proteins. On activation STAT proteins bind to
  • Oligonucleotide sequences comprising DNA regulatory elements of the general sequence TT(N)nAA have been identified (Seidel et al., Proc. Nat. Acad. Sci. USA., 1995, 92. 3041) as STAT response elements. These elements bind STAT proteins in response to signalling molecules such as cytokines.
  • Such an assay has utility in selecting compounds for the treatment of weight, energy balance, haematopoietic, fertility and other disorders modulated by the ob-protein.
  • the assay is especially useful for selecting compounds for the treatment of those disorders related to obesity, anorexia, cachexia and diabetes.
  • the response element and the reporter being expressed in an ob-protein responsive cell line, which cell line is selected from the list consisting of: a hypothalamic derived cell line; a pheochromocytoma derived cell line; an haematopoietic derived cell line; a pancreatic derived cell line; a liver derived cell line; a preadipocyte derived cell line; a skeletal muscle derived cell line; and an ovarian derived cell line; or the response element and the reporter are expressed in a cell line, which cell line (the engineered cell line) is also transfected with a polypeptide which is capable of mediating the stimulation by ob-protein of an ob-protein activated STAT DNA response element and contains the appropriate ST
  • a suitable cell line is a hypothalamic derived cell line.
  • a suitable cell line is a pheochromocytoma derived cell line.
  • a suitable cell line is an haematopoietic derived cell line.
  • a suitable cell line is a pancreatic derived cell line.
  • a suitable cell line is a liver derived cell line.
  • a suitable cell line is a preadipocyte derived cell line.
  • a suitable cell line is a skeletal muscle derived cell line.
  • a suitable cell line is an ovarian derived cell line.
  • the response element and the reporter are expressed in a cell line, which cell line (the engineered cell line) is also transfected with a polypeptide which is capable of mediating the stimulation by ob-protein of an ob-protein activated STAT DNA response element and contains the appropriate STAT proteins.
  • An example of a hypothalamic derived cell line is the neuronal GT1-7 cell line described by W.C.Wetsel in Cellular and Molecular Neurobiology, 1995, 15(1), 43.
  • a pheochromocytoma derived cell is the adrenal pheochromocytoma rat PC12 cells (L.A. Greene and A.S. Tischler, Proc. Natl. Acad. Sci. USA. 1976, 73(7), 2424).
  • haematopoietic derived cell line is the HEL 92.1.7 (ATCC TIB 180) cell line derived from a human erythroleukemia (P. Martin. Science. 1982, 216(4551), 1233).
  • haematopoietic derived cell line is the K562(ATCC CCL-243) cell line derived from human chronic myelogenous leukemia (Proc. Soc. Exp. Biol. Med. 1981, 166, 546 and Blood, 1975, 45, 321).
  • An example of a pancreatic derived cell line is the BetaTC-3 cell line (TJ.
  • pancreatic cell lines include RLN5mF cells, recently reported to respond to leptin (Md Shahidul Islam etal; Biochem Biophys Res Comm, 1997, 238, 851-855)
  • An example of a preadipocyte derived cell line is the 30A5 cell line (Y.
  • preadipocyte derived cell lines include differentiated 3T3-L1 and 3T3-F442A cell lines, both of which are commercially available.
  • An example of a liver derived cell line is the HepG2 cell line (B Cohen etal; Science, 1996, 274, 1185- 1188 and Y Wang etal; J Biol Chem, 1997, 272, 16216-16223) or H35 cell line (Y Wang etal; J Biol Chem, 1997, 272, 16216- 16223).
  • liver derived cell lines are WRL68 and Change liver cells, both of which are available commercially.
  • An example of a skeletal muscle derived cell line is the mouse myotube
  • An example of an ovarian derived cell line is the SK-OV-3 cell line. ATCC number HTB77, (J. Fogh and G Trempe in Human Tumour Cells In Vitro pl55-159, J. Fogh (ed) Plenum Press, New York, 1975; J. Fogh and G Trempe J. Natl. Cancer Inst Bethesda, 1977, 587:209-214)
  • a suitable polypeptide which is capable of mediating the stimulation by ob-protein of an ob-protein activated STAT DNA response element is a functional isoform of the ob-gene receptor, for example that identified in Tartaglia et al., Cell, 1995, 83, 1263.
  • the response element is coupled to a promoter gene, preferably a minimal promoter.
  • a suitable response element is a nucleotide of formula TT(N) n AA, where N is any nucleotide and n is 4, 5 or 6.
  • a favoured response element is selectively activated by the intracellular events mediated the by the ob-protein interacting with its receptor.
  • Such selective response elements can be determined by examining the relative activation of a range of response element-reporter gene constructs when transfected into an ob- responsive cell line by the ob-protein versus other cytokines.
  • a favoured response element is a nucleotide of formula TT(N) n AA. where N is any nucleotide and n is 4 or 5.
  • a further suitable response element is TTCCCGGAA.
  • a further suitable response element is that region of the promoter of a gene regulated by the ob-protein that is required for STAT interactions. This gene will depend on the particular therapeutic use of the compounds to be selected by the assay.
  • a suitable reporter gene is firefly luciferase or chloramphenicol acetyltransferase enzyme.
  • a suitable promoter is a minimal promoter such as the herpes simplex virus thymidine kinase or SV40 promoter.
  • responsive cell lines can be identified using a displacement binding assay. Although binding may not be to a functional long form of the receptor, which is the form that transmits a signal to the cytoplasm. Identification of a functional long form of the receptor may be by PCR or Northern blot analysis (eg. Human ob-receptor: Tartaglia et al., Cell, 1995, 83, 1263). Ultimately responsive cells are detected by monitoring cellular events in the presence of varying concentrations of leptin. Potential methods for identifying candidate cell lines or monitoring these cellular events include the following:- 1. Microphysiometer: This method detects small changes in pH resulting from biochemical changes in the cell. Ob-protein responsive cells upon stimulation may undergo biochemical changes that cause a small change in the extracellular acidification rate which can be detected by a silicon microphysiometer. The microphysiometer biosensor methodology has been reviewed by McConnell, Science, 1992, 257, 1906.
  • Electrophoretic mobility shift assay Nuclear extracts from cells after treatment with ob-protein are mixed with radiolabeled oligonucleotides containing a promiscuous or specific STAT response element DNA sequence. Extracts from cells that respond to the ob-protein may cause a gel shift of the oligonucleotide for the STAT response element.
  • the coupling of receptor activation to the final response through tyrosine phosphorylation of intracellular proteins may be assayed by the use of antibodies recognising phosphorylated tyrosines. More specifically since the leptin receptor may stimulate tyrosine phosphorylation of the JAK/STAT pathway this method provides a method of detecting leptin response cell lines. Specific JAK/ STAT antibodies may be used alongside antibodies for tyrosine phosphorylation to detect leptin activation in a leptin responsive cell line. Inhibition as well as stimulation of protein phosphorylation may occur.
  • Displacement binding After incubation of cell lines with radiolabelled leptin. for example [125 ⁇ _ ⁇ e p tm) e non-specific binding versus specific binding of leptin can studied by the addition of unlabelled leptin. A high specific to nonspecific ratio binding suggests that the cell line may contain the leptin receptor.
  • mRNA for a functional form preferably a functional long form, of the ob-receptor by Northern, RT-PCR or "slot blot" analysis.
  • C-fos mRNA may be detected by Northern, RT-PCR or "slot blot" analysis.
  • Cell lines known to be involved in controlling aspects of the particular disease state for which compounds are being sought are preferred.
  • Cells lines derived from liver, brain, or pancreatic tissue and fibroblasts are particularly useful for "ob-responsive" cells for the assaying of compounds directed at obesity and diabetes.
  • Certain areas of the brain are the focus of weight controlling and energy balance regulating effects of the ob-protein.
  • the liver controls many metabolic processes that modulate lipid and glucose levels.
  • Cells derived from particular regions of these organs containing the appropriate endogenous JAKs, STAT proteins and other intracellular proteins which are required for mediating the effects of the leptin are preferred.
  • the response element, the reporter, and preferably the promoter are suitably incorporated into a vector capable of transfecting the ob-responsive cell line.
  • Suitable vectors are commercially available vectors, such as pGL2-basic luciferase vector (Promega).
  • a suitable configuration of the vector is the STAT DNA response element upstream of a promoter and a reporter gene.
  • a more suitable configuration of the vector is the STAT DNA response element in multiple tandem repeats (2-10) upstream of a thymidine kinase promoter and a luciferase reporter gene
  • Vectors are constructed containing a reporter gene for example firefly luciferase or chloramphenicol acetyltransferase enzyme linked to a minimal promoter for example the herpes simplex virus thymidine kinase or SV40 promoter.
  • a reporter gene for example firefly luciferase or chloramphenicol acetyltransferase enzyme linked to a minimal promoter for example the herpes simplex virus thymidine kinase or SV40 promoter.
  • the DNA fragments for the STAT response element are inserted into the vector using appropriate restriction enzyme sites upstream of the minimal promoter.
  • the response element, the reporter and the promoter are incorporated into the vector using conventional expression techniques, for example the DNA fragments for the response element may be inserted into the vector using appropriate restriction enzyme sites upstream of the minimal promoter.
  • STAT response element-luciferase enzyme reporter systems can be constructed as described by Lamb et al., Blood, 1994, 8, 2063 and Seidel et al, Proc. Nat. Acad. Sci. USA., 1995, 92, 3041.
  • Ob-responsive cells are transfected with the STAT response element- minimal promoter-luciferase reporter constructs using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456). To correct for differences in transfection efficiency, the cells can be co-transfected with a reference plasmid expressing ⁇ -galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate ⁇ -galactosidase, activity.
  • Potentiation or antagonist activity can be assayed by pre- or co-addition of an appropriate concentration of ob-protein to the compound under evaluation and measuring the potentiation or reduction in luciferase response relative to that of ob-protein alone.
  • Standard methods exist for assaying luciferase enzyme activity for example Ow et al. Science, 1986, 234, 856 and de Wet et al, Mol. Cell Biol, 1987, 7, 725. as well as several commercial kits.
  • Stable cell lines can be generated by transfecting an "ob-responsive" cell line with the reporter construct and a selectable marker. Selectable markers are routinely used to generate stable cell lines as described in Recombinant DNA, 2nd edition, J.D. Watson et. al., 1992, page 216. These stably transfected cell lines can be used to generate high throughput assays for compounds that mimic, potentiate or block the physiological effects of the ob-protein.
  • the invention also extends to a compound that mimics, potentiates or inhibits the physiological effect of the ob-protein, when identified by the method disclosed herein.
  • the invention also extends to a kit of parts adapted for use in the method disclosed herein.
  • a compound which mimics the physiological effects of the ob-protein' refers to a compound which is capable of acting in the absence of the ob-protein to either stimulate the ob-protein receptor to provide substantially the same physiological effect as the ob protein or to activate a response down stream of this receptor (post-receptor).
  • a compound that potentiates the physiological effect of the ob-protein' refers to a compound which enhances the potency and/or maximal physiological effect of the ob-protein.
  • a compound that inhibits the physiological effect of the ob-protein' refers to a compound which reduces or substantially blocks the physiological effect of the ob protein.
  • the cDNA encoding the functional form of the polypeptide can be transfected under the control of a constitutive promoter, (eg a viral promotor) or a regulatable promoter to optimise the expression of the polypeptide for the identification of agonists or antagonists as necessary.
  • the response element and the reporter are expressed in a cell line, wherein a constitutive or regulatable promoter has been engineered into a position upstream of the chromosomally encoded gene for the ob-protein recepter by the method of homologous recombination.
  • Ob-responsive cells are transfected with a reporter plasmid containing a STAT response element, in multiple tandem copies upstream of a minimal promoter for example herpes simplex thymidine kinase and a luciferase gene reporter construct using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456).
  • a minimal promoter for example herpes simplex thymidine kinase and a luciferase gene reporter construct
  • the cells can be co-transfected with a reference plasmid expressing ⁇ -galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed.
  • the lysates are assayed for luciferase, and if appropriate ⁇ - galactosidase, activity.
  • Antagonist activity can be assayed by pre- or co-addition of an appropriate concentration of ob-protein to the compound under evaluation and measuring the reduction in luciferase response relative to that of ob-protein alone.
  • Standard methods exist for assaying luciferase enzyme activity for example Ow et al, Science, 1986, 234, 856 and de Wet et al., 1987, 7, 725. as well as several commercial kits.
  • Gtl-7 cells (W.C.Wetsel, Cellular and Molecular Neurobiology, 1995, 15(1), 43) are transfected with a reporter plasmid, pGL2-basic luciferase vector (Promega) containing an insert of an oligonucleotide corresponding to a four fold tandem repeat of the STAT response element, TTCCCGGAA, upstream of the minimal promoter for herpes simplex thymidine kinase (-35 to +10) using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456).
  • the cells can be co-transfected with a reference plasmid expressing ⁇ - galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate ⁇ -galactosidase, activity. Antagonist activity can be assayed by pre- or co-addition of an appropriate concentration of ob-protein to the compound under evaluation and measuring the reduction in luciferase response relative to that of ob-protein alone. Standard methods exist for assaying luciferase enzyme activity for example Ow et al., Science, 1986, 234, 856 and de Wet et al., Mol. Cell Biol, 1987, 7, 725. as well as several commercial kits.
  • Rat PC 12 cells (LA. Greene and A.S. Tischler, Proc. Natl. Acad. Sci. USA. 1976, 73(7), 2424) are transfected with a reporter plasmid, pGL2-basic luciferase vector (Promega) containing an insert of an oligonucleotide corresponding to a four fold tandem repeat of the STAT response element, TTCCCGGAA, upstream of the minimal promoter for herpes simplex thymidine kinase (-35 to +10) using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456).
  • the cells can be co-transfected with a reference plasmid expressing ⁇ - galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate ⁇ -galactosidase, activity. Antagonist and luciferase enzyme activity can be assayed as discussed above.
  • HEL 92.1.7 (ATCC TIB 180) cells derived from a human erythroleukemia (P. Martin, Science. 1982, 216(4551), 1233) are transfected with a reporter plasmid, pGL2-basic luciferase vector (Promega) containing an insert of an oligonucleotide corresponding to a four fold tandem repeat of the STAT response element,
  • TTCCCGGAA upstream of the minimal promoter for herpes simplex thymidine kinase (-35 to +10) using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456).
  • the cells can be co-transfected with a reference plasmid expressing ⁇ -galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate ⁇ -galactosidase, activity. Antagonist and luciferase enzyme activity can be assayed as discussed above.
  • K562 (ATCC CCL-243) cells derived from human chronic myelogenous leukemia (Proc. Soc. Exp. Biol. Med. 1981, 166, 546 and Blood, 1975, 45, 321) are transfected with a reporter plasmid, pGL2-basic luciferase vector (Promega) containing an insert of an oligonucleotide corresponding to a four fold tandem repeat of the STAT response element, TTCCCGGAA, upstream of the minimal promoter for herpes simplex thymidine kinase (-35 to +10) using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456).
  • the cells can be co-transfected with a reference plasmid expressing ⁇ - galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase. and if appropriate ⁇ -galactosidase, activity. Antagonist and luciferase enzyme activity can be assayed as discussed above.
  • Example 5 The insulinoma BetaTC-3 cells (TJ. Kieffer et al., Biochem. and Biophys. Res. Comm., 1996. 224, 552) are transfected with a reporter plasmid, pGL2-basic luciferase vector (Promega) containing an insert of an oligonucleotide corresponding to a four fold tandem repeat of the STAT response element.
  • TTCCCGGAA upstream of the minimal promoter for herpes simplex thymidine kinase (-35 to +10) using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52. 456).
  • the cells can be co-transfected with a reference plasmid expressing ⁇ -galactosidase activity. After a period of transfection ( 12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase. and if appropriate ⁇ -galactosidase, activity. Antagonist and luciferase enzyme activity can be assayed as discussed above.
  • Preadipocyte derived 30A5 cells (Y. Bai et al., J. Biol. Chem.. 1996, 271(24). 13939) are transfected with a reporter plasmid, pGL2-basic luciferase vector (Promega) containing an insert of an oligonucleotide corresponding to a four fold tandem repeat of the STAT response element, TTCCCGGAA. upstream of the minimal promoter for herpes simplex thymidine kinase (-35 to +10) using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456).
  • the cells can be co-transfected with a reference plasmid expressing ⁇ - galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate ⁇ -galactosidase, activity. Antagonist and luciferase enzyme activity can be assayed as discussed above.
  • Example 7 Mouse myotube C2 C12 cells (Nature, 1977, 270, 725) are transfected with a reporter plasmid, pGL2-basic luciferase vector (Promega) containing an insert of an oligonucleotide corresponding to a four fold tandem repeat of the STAT response element, TTCCCGGAA, upstream of the minimal promoter for herpes simplex thymidine kinase (-35 to +10) using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456). To correct for differences in transfection efficiency, the cells can be co- transfected with a reference plasmid expressing ⁇ -galactosidase activity.
  • the cells After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate ⁇ -galactosidase, activity. Antagonist and luciferase enzyme activity can be assayed as discussed above.
  • Example 8 Ovarian SK-OV-3 cells, ATCC number HTB77, (J. Fogh and G Trempe in Human Tumour Cells In Vitro pl55-159, J. Fogh (ed) Plenum Press, New York, 1975; J. Fogh and G Trempe J. Natl. Cancer Inst Bethesda, 1977, 587:209-214) are transfected with a reporter plasmid, pGL2-basic luciferase vector (Promega) containing an insert of an oligonucleotide corresponding to a four fold tandem repeat of the STAT response element.
  • a reporter plasmid pGL2-basic luciferase vector (Promega) containing an insert of an oligonucleotide corresponding to a four fold tandem repeat of the STAT response element.
  • TTCCCGGAA upstream of the minimal promoter for herpes simplex thymidine kinase (-35 to +10) using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456).
  • the cells can be co-transfected with a reference plasmid expressing ⁇ - galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate ⁇ -galactosidase, activity. Antagonist and luciferase enzyme activity can be assayed as discussed above.
  • Hepatoma derived cell lines transfected with the functional form of the leptin receptor (Baumann et al., Proc. Nat. Acad. Sci., 1996, 93, 8374-8378) are co- transfected with a reporter plasmid, pGL2-basic luciferase vector (Promega) containing an insert of an oligonucleotide corresponding to a four fold tandem repeat of the STAT response element, TTCCCGGAA, upstream of the minimal promoter for herpes simplex thymidine kinase (-35 to +10) using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456).
  • the cells can be co-transfected with a reference plasmid expressing ⁇ - galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate ⁇ -galactosidase, activity. Antagonist and luciferase enzyme activity can be assayed as discussed above.
  • WRL68 cells were grown to confluence in their standard culture medium in the simultaneous presence of 10% foetal calf serum. At confluence the cells were transferred to serum-free medium for a minimum of 18 hours (lowering the serum concentration may also produce similar results). Serum-starved cells were then treated with leptin or with serum (as positive control for c-fos upregulation) for varying time periods from 5 minutes to 2 hours. RNA was extracted from the cells and subjected to gel electrophoresis and northern blotting. The blotted RNA was then probed with a c-fos labelled probe to analyze the expression of c-fos, the data being normalised by analysing the expression of beta-actin.
  • WRL68 cells Leptin treatment significantly enhanced c-fos expression in WRL68 cells (see Table 1) as would the positive control serum, and hence is expected to activate STATs. Therefore WRL68 cells is expected to be suitable for identification of leptin mimetics. Other cell lines could also be identified via analysis of c-fos expression in response to leptin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a trait à un procédé de détection d'un composé qui imite, potentialise ou inhibe l'effet physiologique de la protéine ob, ce procédé consistant: (a) pour un composé qui imite l'effet physiologique de la protéine ob, à évaluer l'effet du composé sur un transducteur de signal activé par la protéine ob et un activateur d'élément de réponse d'ADN de transcription (STAT) couplé avec un gène marqueur; ou (b) pour un composé qui potentialise ou inhibe l'effet physiologique de la protéine ob, à évaluer l'effet du composé sur la réponse produite par la protéine ob, sur un élément de réponse d'ADN STAT activé par la protéine ob couplé avec un gène marqueur; où l'élément de réponse et le marqueur sont exprimés dans une lignée cellulaire réactive à la protéine ob, lignée sélectionnée à partir d'une liste constituée par: une lignée cellulaire de source hypothalamique; une lignée cellulaire de source phéochromocytomique; une lignée cellulaire de source hématopoïétique; une lignée cellulaire de source pancréatique; une lignée cellulaire de source hépatique; une lignée cellulaire de préadipocytes; une lignée cellulaire d'un muscle squelettique; une lignée cellulaire de source ovarienne; ou l'élément de réponse et le marqueur sont exprimés dans une lignée cellulaire (la lignée cellulaire modifiée génétiquement) qui est aussi transfectée avec un polypeptide capable de servir de médiateur dans la stimulation par la protéine ob d'un élément de réponse d'ADN STAT activé par la protéine ob et qui contient les protéines STAT appropriées.
EP97910545A 1996-11-01 1997-10-30 Procede pour la detection de composes modulant les effets de la proteine de l'obesite (ob) Withdrawn EP0951564A1 (fr)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
GB9622866 1996-11-01
GB9622868 1996-11-01
GB9622848 1996-11-01
GBGB9622866.3A GB9622866D0 (en) 1996-11-01 1996-11-01 Novel method
GB9622850 1996-11-01
GBGB9622850.7A GB9622850D0 (en) 1996-11-01 1996-11-01 Novel method
GB9622847 1996-11-01
GB9622870 1996-11-01
GBGB9622849.9A GB9622849D0 (en) 1996-11-01 1996-11-01 Novel method
GBGB9622869.7A GB9622869D0 (en) 1996-11-01 1996-11-01 Novel method
GBGB9622867.1A GB9622867D0 (en) 1996-11-01 1996-11-01 Novel method
GBGB9622870.5A GB9622870D0 (en) 1996-11-01 1996-11-01 Novel method
GBGB9622868.9A GB9622868D0 (en) 1996-11-01 1996-11-01 Novel method
GBGB9622865.5A GB9622865D0 (en) 1996-11-01 1996-11-01 Novel method
GB9622867 1996-11-01
GB9622849 1996-11-01
GBGB9622847.3A GB9622847D0 (en) 1996-11-01 1996-11-01 Novel method
GBGB9622851.5A GB9622851D0 (en) 1996-11-01 1996-11-01 Novel method
GBGB9622848.1A GB9622848D0 (en) 1996-11-01 1996-11-01 Novel method
GB9622869 1996-11-01
GB9622851 1996-11-01
GB9622865 1996-11-01
PCT/GB1997/002988 WO1998020158A1 (fr) 1996-11-01 1997-10-30 Procede pour la detection de composes modulant les effets de la proteine de l'obesite (ob)

Publications (1)

Publication Number Publication Date
EP0951564A1 true EP0951564A1 (fr) 1999-10-27

Family

ID=27581686

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97910545A Withdrawn EP0951564A1 (fr) 1996-11-01 1997-10-30 Procede pour la detection de composes modulant les effets de la proteine de l'obesite (ob)

Country Status (13)

Country Link
EP (1) EP0951564A1 (fr)
JP (1) JP2001503982A (fr)
KR (1) KR20000053007A (fr)
AR (1) AR010262A1 (fr)
AU (1) AU4789297A (fr)
CA (1) CA2270431A1 (fr)
CZ (1) CZ149999A3 (fr)
IL (1) IL129685A0 (fr)
NO (1) NO992107L (fr)
NZ (1) NZ335489A (fr)
PL (1) PL333187A1 (fr)
TR (1) TR199900963T2 (fr)
WO (1) WO1998020158A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293533B1 (it) * 1997-07-14 1999-03-01 Angeletti P Ist Richerche Bio Metodo per la selezione di molecole in grado di mimare, inibire o potenziare gli effetti della interazione tra leptina e cellule che
GB9814199D0 (en) * 1998-06-30 1998-08-26 Univ Buckingham Novel method
WO2000007014A2 (fr) * 1998-07-28 2000-02-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Induction de genes a mediation par la leptine
GB9828087D0 (en) * 1998-12-18 1999-02-17 Smithkline Beecham Plc Novel method
ATE300611T1 (de) 2000-05-22 2005-08-15 Vlaams Interuniv Inst Biotech Auf rezeptorgrundlage arbeitende screening- verfahren für protein wechselwirkungen
GB0019327D0 (en) * 2000-08-08 2000-09-27 Buchanan Baillie Hamilton Paul Slimming system
CA2585549A1 (fr) 2004-11-18 2006-05-26 Vib Vzw Domaine de fibronectine iii servant d'antagonistes de recepteurs de la leptine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643748A (en) * 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
CA2215387A1 (fr) * 1995-03-20 1996-09-26 Michael R. Briggs Modulateurs du gene ob et methodes de depistage connexes
US5712094A (en) * 1995-03-27 1998-01-27 Ligand Pharmaceuticals, Inc. Methods for detecting modulators of cytokine action
KR19990022134A (ko) * 1995-05-30 1999-03-25 페터 제이 기딩스 비만 단백질의 효과를 조절하는 화합물의 검출 방법
JP2000511406A (ja) * 1996-04-22 2000-09-05 メルク エンド カンパニー インコーポレーテッド レプチンアッセイ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9820158A1 *

Also Published As

Publication number Publication date
NO992107D0 (no) 1999-04-30
WO1998020158A1 (fr) 1998-05-14
CZ149999A3 (cs) 1999-10-13
TR199900963T2 (xx) 1999-08-23
AU4789297A (en) 1998-05-29
NO992107L (no) 1999-06-30
AR010262A1 (es) 2000-06-07
KR20000053007A (ko) 2000-08-25
NZ335489A (en) 2001-01-26
IL129685A0 (en) 2000-02-29
CA2270431A1 (fr) 1998-05-14
JP2001503982A (ja) 2001-03-27
PL333187A1 (en) 1999-11-22

Similar Documents

Publication Publication Date Title
André et al. A novel isoform of the orphan nuclear receptor RORβ is specifically expressed in pineal gland and retina
Rishi et al. Estradiol regulation of the human retinoic acid receptor α gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs
Chesnokov et al. p53 inhibits RNA polymerase III-directed transcription in a promoter-dependent manner
Albanese et al. Development of a bioassay for FSH using a recombinant human FSH receptor and a cAMP responsive luciferase reporter gene
Brasier et al. Synergistic enhansons located within an acute phase responsive enhancer modulate glucocorticoid induction of angiotensinogen gene transcription
AU715215B2 (en) Method for the detection of compounds that modulate the effects of the obese protein
KIM et al. Angiotensin II-responsive element is the insulin-responsive element in the adipocyte fatty acid synthase gene: role of adipocyte determination and differentiation factor 1/sterol-regulatory-element-binding protein 1c
Kataoka et al. Signaling events initiated by transforming growth factor-beta 1 that require Gi alpha 1.
Rydziel et al. Cortisol represses insulin-like growth factor II receptor transcription in skeletal cell cultures
EP0951564A1 (fr) Procede pour la detection de composes modulant les effets de la proteine de l'obesite (ob)
Monla et al. Cell type-specific regulation of transcription by cyclic adenosine 3,'5'-monophosphate-responsive elements within the calcitonin promoter.
MXPA97009360A (en) Method for the detection of compounds that modulate the effects of the obesi protein
De Groot et al. Up-regulation of Jun/AP-1 during differentiation of N1E-115 neuroblastoma cells
CA2194361A1 (fr) Procede pour identifier les acides nucleiques codant des proteines d'activation du promoteur c-fos
Buchou et al. Fibroblast growth factor‐dependent mitogenic signal transduction pathway in chemically transformed mouse fibroblasts is similar to but distinct from that initiated by phorbol esters
US20030224456A1 (en) Method for the detection of compounds that modulate the effects of the obese (OB) protein
CA2286894A1 (fr) Regulateurs de l'expression genique de la proteine ucp2
WO1993022331A9 (fr) Crabp-i et crabp-ii humaines
EP0640093A1 (fr) Crabp-i et crabp-ii humaines
Quarles et al. Developmental regulation of osteocalcin expression in MC3T3‐E1 osteoblasts: Minimal role of the proximal E‐box cis‐acting promoter elements
US20020068300A1 (en) Method for the detection of compounds that modulate the effects of the obese protein
BILLESTRUP et al. Molecular mechanism of growth hormone signalling
US20040038315A1 (en) Novel method
WO2000037675A2 (fr) Nouveau procede
MXPA99004184A (en) Method for the detection of compounds that modulate the effects of the obese (ob) protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 19990427

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

17Q First examination report despatched

Effective date: 20030924

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040205

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1023369

Country of ref document: HK